Acting Attorney General Todd Blanche signed an order on April 23 reclassifying state-licensed medical marijuana from Schedule I to Schedule III under federal law - a policy shift that, while short of full federal legalization, rewrites the financial and regulatory calculus for every licensed cannabis business in the country. Cannabis remains illegal at the federal level. What changes is how the federal government treats the businesses selling it and the scientists studying it.
For dispensary operators and multi-state operators (MSOs), the most immediate consequence is the potential end of IRC Section 280E's grip on their income statements. Under Schedule I classification, 280E barred cannabis businesses from deducting ordinary business expenses - payroll, rent, marketing, POS infrastructure - on their federal returns, leaving operators taxed on gross profit rather than net income. That single provision has functioned as a structural tax penalty that no other legal retail sector faces. Operators running IndicaOnline cannabis POS systems or other retail technology platforms have long absorbed those costs without the deduction relief that any comparable licensed retailer would expect as standard. Schedule III status changes that equation in a meaningful way for medical cannabis licensees, though the legal mechanics will require IRS and DOJ guidance to fully settle.
The reclassification targets medical cannabis and FDA-approved products specifically. Recreational cannabis businesses are not yet covered by this order, which creates a compliance split that multi-state operators running both adult-use and medical programs will need to address carefully with their tax counsel. The June hearing the Trump administration has scheduled will open a pathway to evaluate broader federal changes - including, potentially, recreational reclassification - but that outcome remains entirely speculative for now.
What the Tax Shift Actually Means for Licensed Operators
280E has been the defining constraint of cannabis business economics since at least 2012. Because cannabis was Schedule I, the IRS applied a tax code provision originally designed to deny deductions to drug traffickers - and cannabis businesses, regardless of state licensure, qualified. Effective federal tax rates for dispensary operators often ran well above what any comparable retail business would pay. That compressed margins, constrained expansion capital, and made it structurally harder to compete with illicit market pricing.
Schedule III status, if extended in practice to state-licensed medical cannabis businesses through IRS rulemaking, means those businesses can deduct cost of goods sold and ordinary business expenses the way any other retailer would. For a dispensary carrying significant overhead - staff, compliance systems, seed-to-sale tracking software, compliant packaging, product testing fees - the difference on a federal tax bill could be substantial. Terry Mendez, CEO of Safe Harbor Financial, called it "the most significant federal action on cannabis policy in more than 50 years." That framing is hard to argue with when you consider what 280E has cost the industry cumulatively.
Investors and real estate partners are paying attention too. Anthony Coniglio, CEO of NewLake Capital Partners, described the change as "a material shift not only for operators and patients, but also for investors, lenders, and real estate partners evaluating the cannabis sector." Cannabis real estate has operated under a particular kind of capital friction - lenders reluctant to touch federally illegal collateral, sale-leaseback structures complicated by Schedule I exposure. Rescheduling does not eliminate that friction overnight, but it signals a different federal posture.
Banking and Payments: Still Unresolved, Still Pressing
Here's the catch: Schedule III reclassification does not, on its own, fix the banking problem. Cannabis businesses have operated largely outside the conventional banking system precisely because federal law made deposit-taking and lending to cannabis operators a compliance liability for financial institutions. The Safe Banking Act - which would have provided clear federal protections for banks serving state-licensed cannabis businesses - has stalled repeatedly in Congress.
Rescheduling changes the backdrop but does not substitute for banking legislation. Dispensary operators will likely still face limited access to conventional checking accounts, merchant processing, and business credit lines in the near term. Cashless ATM workarounds, cash-heavy operations, and alternative payment processors will remain operational realities for most retail locations until either Congress acts or federal banking regulators issue clear guidance that Schedule III status translates to reduced institutional risk. Operators should not restructure their treasury or payments infrastructure based on rescheduling alone without specific guidance from legal and compliance counsel.
Research Access Opens - With Real Clinical Implications
For the scientific and clinical side, the change is more straightforward. Schedule I classification required DEA licensing and a maze of federal approvals for any researcher wanting to study cannabis - restrictions that no other pharmaceutical compound of comparable clinical interest carried. That regulatory barrier slowed clinical trial development, limited the supply of research-grade cannabis available to institutions, and kept the evidence base thinner than patient adoption warranted.
Schedule III opens the supply chain for research cannabis and reduces the procedural burden on institutions applying to conduct studies. Organizations like Realm of Caring, which is partnering with the Johns Hopkins Behavioral Pharmacology Research Unit on a national medicinal cannabis use registry, stand to benefit directly from fewer federal roadblocks. As Sasha Kalcheff-Korn, Realm of Caring's executive director, put it, rescheduling "will make it easier to complete this research and conduct future studies." What that research ultimately confirms or complicates about cannabis's clinical profile remains to be seen - the science will take time.
Not everyone is satisfied with this framing. Pam Jenkins, CEO of Shatterproof, flagged the public health dimension: "As states evaluate access to these products, we have a responsibility to ensure that young people are protected, that clinicians have clear guidance, and that the public understands the real risks." That concern is legitimate. Rescheduling changes the federal classification - it does not resolve open questions about youth access, potency standards, product testing consistency, or the adequacy of state-level compliance frameworks. Dispensary operators, for their part, have a compliance obligation to age-gate sales rigorously regardless of how federal scheduling evolves.
The Policy Floor Has Shifted - But the Ceiling Is Still Unknown
The June federal hearing is the next marker worth watching. It will determine whether rescheduling stays confined to medical cannabis and FDA-approved products, or whether the administration moves toward a broader reclassification framework that touches adult-use as well. The gap between those two outcomes is significant for operators whose revenue depends primarily on recreational sales - which is the majority of the licensed market in most adult-use states.
What is clear right now: the federal government has moved off a position it held for more than five decades. The operational and financial implications for licensed medical cannabis businesses are real and material. The uncertainty about scope, IRS interpretation, and banking treatment is equally real. Operators who read this as a green light to restructure their business assumptions without updated legal and tax guidance will get ahead of themselves. But operators who treat it as background noise will miss a genuine shift in the policy foundation their businesses rest on.
